Doctor's Bio
Mehmet Asim Bilen, MD, serves as Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Bilen joined the clinical staff at Grady’s Cancer Center as a practicing physician in July 2016. He is actively involved in clinical research and patient care in the area of genitourinary cancers. He works closely with the Fellowship Program of the Department of Hematology and Medical Oncology by educating fellows on genitourinary oncology. He also serves on the Grady Clinical Research Committee. Dr. Bilen holds professional memberships with American Association for Cancer Research and American Society of Clinical Oncology.
Board Certifications
American Board of Internal Medicine
Affiliations
Emory
Education & Training
- Medical School: Hacettepe University Medical School
- Internship: Baylor College of Medicine
- Residency: Baylor College of Medicine
Fellowships
University of Texas MD Anderson Cancer Center
Locations and Directions
Correll Pavilion
Phone: (404) 616-1000
Location:
80 Gilmer St. SE
Atlanta, GA 30303
Publications
- Mapping heterogeneity in the tumor microenvironment of renal cell carcinoma through single-cell omics.
Gok Yavuz B, Khanmammadova N, Majeed Z, Ali MIH, Hasanov M, Bilen MA, Singer EA, Hasanov E
Trends in cancer. 2025;
PMID: 41339185 - Response to Letter to the Editor Regarding: 'Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer'.
Bilen MA, Lowentritt B, Khilfeh I, Rossi C, Du S, Kinkead F, Diaz L, Pilon D, Ellis L, Shore ND
Advances in therapy. 2025;
PMID: 41313547 - Targeting p300 and CBP abolishes HOXB13-loss-induced lipogenesis and tumor metastasis.
Lu X, Peng L, Chu Q, Ye S, Liu M, Hussain M, Bilen MA, Harik LR, Melamed J, Zhao JC, Yu J
JCI insight. 2025;
PMID: 41277556 - Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study.
Kopp RM, Massari F, Grande E, Schieber TJ, Ürün Y, Kopecký J, Molina-Cerrillo J, Basso U, Kucharz J, Büttner T, Pichler R, Fiala O, Myint ZW, Galli L, Buchler T, Rizzo M, Bolek H, Bourlon MT, Conteduca V, Pinto A, Rizzo A, Rosellini M, Roviello G, Zgura A, Mollica V, Partl A, Yildirim A, Akova U, Buti S, Monteiro FSM, Soares A, Porta C, Bilen MA, Li H, Santoni M
Cancer immunology, immunotherapy : CII. 2025;74(12):374.
PMID: 41236632 - Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.
Massari F, Rosellini M, Melichar B, Grande E, Bourlon MT, Li H, Fiala O, Park SH, Fita MJJ, Taha T, Molina-Cerrillo J, Santini D, de Liañ AG, Büttner T, Scagliarini S, Manneh Kopp R, Zeppellini A, Ghosn M, Conteduca V, Bölek H, Rizzo A, Ansari J, Mollica V, Zgura A, Filosa A, Yildirim A, Akova U, Monteiro FSM, Buti S, Soares A, Bilen MA, Ürün Y, Santoni M
JCO global oncology. 2025;
PMID: 41160781 - Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study.
Jindal T, Jiang CY, Alhalabi O, Davidsohn M, Freeman D, Epstein IY, Bakaloudi DR, Talukder R, Nizam A, Nguyen CB, Oh E, Tsung I, Glover MJ, Khaki AR, Taylor AK, Jaime-Casas S, Jang A, Lemke E, Pywell C, Evans ST, Shin D, Bilen MA, Basu A, Kilari D, Tripathi A, Brown J, Emamekhoo H, Davis NB, Shah S, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS
Urologic oncology. 2025;
PMID: 41152111 - Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617.
Panian J, Henderson NC, Herchenhorn D, Barata PC, Bilen MA, Graham L, Heath E, Hwang C, Supernois A, Kilari D, Thapa B, Koshkin VS, Jindal T, Nauseef JT, Sokolova A, Amery T, Zakharia Y, Schweizer MT, Raychaudhuri R, Reichert ZR, Dorff T, Armstrong AJ, Wang J, Alva A, McKay RR
The oncologist. 2025;
PMID: 41124032 - Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.
Jiang CY, Hwang H, Epstein IY, Bakaloudi DR, Talukder R, Taylor AK, Nizam A, Jindal T, Glover MJ, Khaki AR, Barata PC, Nguyen CB, Oh E, Davis NB, Mabey H, Hoimes CJ, Evans ST, Abuqayas B, Lemke E, Tsung I, Qiao W, Kilari D, Zakharia Y, Bilen MA, Milowsky MI, Shah SA, Gupta S, Emamekhoo H, Bellmunt J, Alva AS, Grivas P, Msaouel P, Koshkin VS, Campbell MT, Alhalabi O
The oncologist. 2025;
PMID: 41056445 - Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study.
Nizam A, Nguyen CB, Li J, Zabor EC, Msaouel P, Jiang CY, Alhalabi O, Oh E, Davidsohn MP, Epstein IB, Bakaloudi DR, Talukder R, Jindal T, Taylor AK, Glover MJ, Khaki AR, Lemke E, Mabey H, Abuqayas B, Jang A, Brown JR, Evans ST, Pywell C, Basu A, Bilen MA, Barata PC, Zakharia Y, Milowsky MI, Kilari D, Hoimes CJ, Shah SA, Emamekhoo H, Davis NB, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS
Cancer medicine. 2025;14(19):e71284.
PMID: 41031719 - Phase I study of palbociclib with cisplatin or carboplatin in the management of patients with advanced pancreatic cancer.
Alese OB, Harvey RD, Wu C, Hitron E, Collins H, Scott S, Steuer C, Bilen MA, Carthon BC, Switchenko JM, Ramalingam SS, Owonikoko TK
The oncologist. 2025;
PMID: 40973049
PLANNING
PREPARING FOR YOUR VISIT
Whether you’re a patient or you’re visiting one, a little planning beforehand can make your visit to Grady easier and more comfortable. Here, you’ll find everything you need to prepare for your visit, including an appointment checklist, admissions information, dining options, and much more.